Importance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: Further analysis of the SENTIS trial

Journal of NeuroInterventional Surgery

Volumn 5, Issue SUPPL.1, 2013, Pages

  Shuaib, Ashfaq ^a   Schwab, Stefan ^b   Rutledge, J Neal ^c   Starkman, Sidney ^d   Liebeskind, David S ^d   Bernardini, Gary L ^e   Boulos, Alan ^e   Abou Chebl, Alex ^f   Huang, David Y ^g   Vanhooren, Geert ^h   Cruz Flores, Salvador ⁱ   Klucznik, Richard Paul ^j   Saver, Jeffrey L ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c University Medical Center Brackenridge   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ALBANY MEDICAL CENTER   (United States)

^f University of Louisville School of Medicine   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h General Hospital St Jan   (Belgium)

ⁱ SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HOUSTON METHODIST HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; GLASGOW OUTCOME SCALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

COHORT STUDIES; ENDPOINT DETERMINATION; FOLLOW-UP STUDIES; HUMANS; PATIENT SELECTION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 84877912655     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2012-010562     Document Type: Article

References (11)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke 2011;42:2356-62.
3. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
5. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. JAMA 1999;282:2003-11.
6. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007;6:215-22. (Pubitemid 46237760)
7. Zivin JA, Albers GW, Bornstein N, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 2009;40:1359-64.
8. Diener HC, Schneider D, Lampl Y, et al. DP-bpp, a membrane-activated metal ion chelator, as a neuroprotective therapy in ischemic stroke. Stroke 2008;39:1774-8.
9. Stroke Therapy Academic Industry Roundtable II. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598-606.
10. Weir CJ, Kaste M, Lees KR. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke 2004;35:2111-16. (Pubitemid 39129570)
11. Shuaib A, Bornstein NM, Diener HC, et al. Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke Trial. Stroke 2011;42:1680-90.